ATE411010T1 - Topische nanopartikel-spironolacton-formulierung - Google Patents

Topische nanopartikel-spironolacton-formulierung

Info

Publication number
ATE411010T1
ATE411010T1 AT02808245T AT02808245T ATE411010T1 AT E411010 T1 ATE411010 T1 AT E411010T1 AT 02808245 T AT02808245 T AT 02808245T AT 02808245 T AT02808245 T AT 02808245T AT E411010 T1 ATE411010 T1 AT E411010T1
Authority
AT
Austria
Prior art keywords
nanoparticles
spironolactone
topical
formulation
spironolactone formulation
Prior art date
Application number
AT02808245T
Other languages
English (en)
Inventor
Guy Vergnault
Pascal Grenier
Alain Nhamias
Dieter Scherer
Petra Beck
Patricia Cancade
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of ATE411010T1 publication Critical patent/ATE411010T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
AT02808245T 2002-12-13 2002-12-13 Topische nanopartikel-spironolacton-formulierung ATE411010T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2002/005680 WO2004054549A1 (en) 2002-12-13 2002-12-13 A topical nanoparticulate spironolactone formulation

Publications (1)

Publication Number Publication Date
ATE411010T1 true ATE411010T1 (de) 2008-10-15

Family

ID=32526735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02808245T ATE411010T1 (de) 2002-12-13 2002-12-13 Topische nanopartikel-spironolacton-formulierung

Country Status (11)

Country Link
US (1) US8003690B2 (de)
EP (1) EP1569623B1 (de)
JP (1) JP2006511525A (de)
CN (1) CN1310648C (de)
AT (1) ATE411010T1 (de)
AU (1) AU2002356294A1 (de)
BR (1) BR0215979A (de)
CA (1) CA2509101A1 (de)
DE (1) DE60229450D1 (de)
MX (1) MXPA05006311A (de)
WO (1) WO2004054549A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606861C (en) * 2005-05-05 2012-08-07 Sanofi-Aventis U.S. Llc Stable nanoparticle formulations
WO2008058755A1 (en) * 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
CN101322712B (zh) * 2007-06-14 2010-10-13 沈阳市万嘉生物技术研究所 一种前列地尔纳米粒制剂及其制备方法
US20100279934A1 (en) * 2008-01-02 2010-11-04 Kringle Pharma, Inc. Topical compositions for delivery of proteins and peptides
US20090203628A1 (en) * 2008-02-12 2009-08-13 Jan Marini Composition, Method And Kit For Treating Skin Disorders And Improving Skin Condition
EP2378872A4 (de) 2008-12-18 2012-05-16 B Eugene Guthery Behandlungsplan für acne vulgaris
MX2012007234A (es) 2009-12-22 2012-07-30 Leo Pharma As Nanocristales de monohidrato de calciprotiol.
HRP20201241T1 (hr) 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
GB201118193D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to oranic compounds
GB201118198D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
CN103301320A (zh) * 2013-07-03 2013-09-18 彭中平 一种祛痘止痒搽剂及其配制方法
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
US10792293B2 (en) * 2015-07-31 2020-10-06 Hamidreza Kelidari Topical nanodrug formulation
US9757394B2 (en) 2015-10-30 2017-09-12 Cmp Development Llc Spironolactone aqueous formulations
US10493083B2 (en) 2015-10-30 2019-12-03 Cmp Development Llc Spironolactone aqueous compositions
US11524016B2 (en) * 2020-07-17 2022-12-13 Amy Thorne Compositions and methods for the topical administration of spironolactone for the treatment of cutaneous signs of excess androgen and chronic stress response
US20230414511A1 (en) 2020-11-17 2023-12-28 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery
CN118632687A (zh) * 2021-11-11 2024-09-10 阿尔库缇斯生物疗法股份有限公司 用于深层皮肤药物递送的螺内酯药物组合物
EP4687913A2 (de) * 2023-03-30 2026-02-11 Celista Pharmaceuticals Llc Sprühbare flüssige spironolacton-zusammensetzungen

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011316A (en) 1975-02-24 1977-03-08 Research Institute For Medicine And Chemistry Inc. Cyclohexa-2,5-diene-1-thiones
WO1983000294A1 (en) * 1981-07-23 1983-02-03 Little Inc A Micellular drug delivery system
SE462894B (sv) * 1985-10-28 1990-09-17 Biogram Ab Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning
DE3623193A1 (de) * 1986-07-10 1988-01-14 Gruenenthal Gmbh Neue verbindungen, diese enthaltende arzneimittel und verfahren zu deren herstellung
DE3623376A1 (de) 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
US4837211A (en) 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Spironolactone composition
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2871776B2 (ja) 1989-03-28 1999-03-17 カロライナ メディカル プロダクツ インコーポレイテッド スピロノラクトン組成物
EP0410348A1 (de) 1989-07-26 1991-01-30 G.D. Searle & Co. Topische Spironolakton-Zusammensetzung
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5506222A (en) * 1991-09-25 1996-04-09 Laboratorios Beta S.A. Method and composition for treating increased androgenic activity
JPH05331066A (ja) 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US6228383B1 (en) * 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
DE19800250A1 (de) 1997-01-13 1998-08-06 Winter Cvd Technik Gmbh Schleifkörper
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
DK0996429T3 (da) * 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
WO1999029300A1 (en) 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US6013637A (en) * 1998-06-12 2000-01-11 Dermik Laboratories Inc. Anti-acne method and composition
WO1999065469A2 (en) 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
WO2001041770A2 (en) 1999-12-08 2001-06-14 Pharmacia Corporation Nanoparticulate eplerenone compositions
FR2803203B1 (fr) 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
GB0114532D0 (en) 2001-06-14 2001-08-08 Jagotec Ag Novel compositions

Also Published As

Publication number Publication date
BR0215979A (pt) 2005-11-01
CN1741794A (zh) 2006-03-01
WO2004054549A1 (en) 2004-07-01
DE60229450D1 (de) 2008-11-27
US20060067892A1 (en) 2006-03-30
US8003690B2 (en) 2011-08-23
CA2509101A1 (en) 2004-07-01
MXPA05006311A (es) 2006-02-08
EP1569623B1 (de) 2008-10-15
AU2002356294A1 (en) 2004-07-09
CN1310648C (zh) 2007-04-18
JP2006511525A (ja) 2006-04-06
EP1569623A1 (de) 2005-09-07

Similar Documents

Publication Publication Date Title
DE60229450D1 (de) Topische nanopartikel-spironolacton-formulierung
Gao et al. Thermoresponsive polymer-encapsulated hollow mesoporous silica nanoparticles and their application in insecticide delivery
Nakamura et al. Synthesis and characterization of organosilica nanoparticles prepared from 3-mercaptopropyltrimethoxysilane as the single silica source
Niculae et al. Rice bran and raspberry seed oil-based nanocarriers with self-antioxidative properties as safe photoprotective formulations
Martín-de-Lucía et al. Combined toxicity of graphene oxide and wastewater to the green alga Chlamydomonas reinhardtii
Osminkina et al. Nanoparticles prepared from porous silicon nanowires for bio-imaging and sonodynamic therapy
Gattás-Asfura et al. Characterization and 2D self-assembly of CdSe quantum dots at the air− water interface
GB0119480D0 (en) Novel compositions
Gao et al. Decorating CdTe QD-embedded mesoporous silica nanospheres with Ag NPs to prevent bacteria invasion for enhanced anticounterfeit applications
Arduini et al. Self-organized fluorescent nanosensors for ratiometric Pb2+ detection
Hoffmeister et al. Hydrogels containing redispersible spray-dried melatonin-loaded nanocapsules: a formulation for transdermal-controlled delivery
ATE550379T1 (de) Wässrige klebstoff-dispersionen
CY1107810T1 (el) Συνθεσεις οι οποιες εχουν ενα συνδυασμο χαρακτηριστικων αμεσης απελευθερωσης και ελεγχομενης απελευθερωσης
SG170094A1 (en) Pulsed growth of gan nanowires and applications in group iii nitride semiconductor substrate materials and devices
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
Barbinta-Patrascu et al. Silver-based biohybrids “green” synthesized from Chelidonium majus L.
Zeigler et al. Hybrid semiconducting polymer nanoparticles as polarization-sensitive fluorescent probes
Ribeiro et al. Synthesis and Characterization of Perylenediimide Labeled Core− Shell Hybrid Silica− Polymer Nanoparticles
Huang et al. A highly efficient bactericidal surface based on the co-capture function and photodynamic sterilization
BRPI0407548A (pt) composições compreendendo um componente polissacarìdeo e uma ou mais camadas de revestimento
Kobayashi et al. Direct coating of quantum dots with silica shell
Suksri et al. Interaction of nicotine with magnesium aluminum silicate at different pHs: characterization of flocculate size, zeta potential and nicotine adsorption behavior
Donners et al. Fabrication of Organic− Inorganic Semiconductor Composites Utilizing the Different Aggregation States of a Single Amphiphilic Dendrimer
Barbinta-Patrascu et al. Photophysical studies on biocomposites based on carbon nanotubes and chlorophyll-loaded biomimetic membranes
CA2387142A1 (en) Silicon nanoparticle stimulated emission devices

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties